SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Surgical Innovation | SI-BONE's iFuse Implant System drives 22.6% YoY growth, establishing the company as a pioneer in minimally invasive sacroiliac joint surgery |
Financial Health | Strong Q1 2025 performance with $47.3M in sales, 25% YoY increase. Healthy 79.25% gross margin and solid cash position, despite current overvaluation |
Growth Trajectory | Analysts project 15-20%+ annual revenue growth. New product launches and FDA Breakthrough Device Designations poised to expand addressable market |
Market Dynamics | Average analyst price target of $28.50. NTAP reimbursement of $3,960 for iFuse TORQ TNT expected in Q4 2025, potentially catalyzing adoption |
Metrics to compare | SIBN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSIBNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −35.8x | −4.0x | −0.5x | |
PEG Ratio | −0.87 | 0.47 | 0.00 | |
Price/Book | 3.8x | 3.5x | 2.6x | |
Price / LTM Sales | 3.4x | 2.0x | 3.2x | |
Upside (Analyst Target) | 63.0% | 36.5% | 50.1% | |
Fair Value Upside | Unlock | 9.5% | 8.6% | Unlock |